Ulka Vaishampayan, MD
Internal Medicine · Ann Arbor, MINPI 1659318640
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $597,344 of the $995,573 with a category attached, or 60.0%. 29 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 25.9% of the total. Reporting peaked in 2019 at $302,013 and has fallen 76.5% since, to $70,927 in 2025. Among internal medicine clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 837 payments — averaging $1189.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$258K
- Exelixis Inc.$212K
- Bayer$199K
- Pfizer$68K
- Sanofi$42K
- Merck$38K
- plus $178K from 23 others
Across 1,342 payments — averaging $24,405 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$22.6M
- Genentech, Inc.$3.3M
- Alkermes, Inc.$3.2M
- Exelixis Inc.$781K
- AbbVie$524K
- Takeda Pharmaceuticals U.S.A., Inc.$319K
- plus $2M from 18 others
What the payments were for
- Consulting fees$294,00130%
- Speaking & faculty fees$597,34460%
- Travel & lodging$91,2959%
- Food & beverage$12,3971%
- Education$5360%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 201 | $257,862 |
| Exelixis Inc. | 202 | $212,122 |
| Bayer | 167 | $199,278 |
| Pfizer | 54 | $67,810 |
| Sanofi | 28 | $42,459 |
| Merck | 27 | $37,645 |
| Novartis | 21 | $33,382 |
| Alkermes, Inc. | 20 | $25,344 |
| Astellas Pharma US Inc | 12 | $16,525 |
| Gilead | 17 | $15,787 |
| EMD Serono, Inc. | 12 | $15,558 |
| Eisai Inc. | 16 | $15,151 |
| Advanced Accelerator Applications | 5 | $12,519 |
| Johnson & Johnson(2 entities) | 14 | $9,315 |
| AVEO Pharmaceuticals, Inc. | 11 | $8,200 |
| Genentech, Inc. | 6 | $5,029 |
| Seagen Inc. | 4 | $4,506 |
| EMD Serono Research & Development Institute, Inc. | 1 | $3,800 |
| Sumitomo Pharma America, Inc. | 1 | $3,100 |
| Helsinn Healthcare SA | 1 | $3,000 |
| AstraZeneca | 6 | $2,172 |
| Aadi Bioscience, Inc. | 1 | $1,500 |
| Telix Pharmaceuticals | 3 | $1,215 |
| Janssen Scientific Affairs, LLC | 1 | $818 |
| Daiichi Sankyo Inc. | 1 | $650 |
| Bristol Myers Squibb | 2 | $518 |
| Olympus America Inc. | 1 | $134 |
| Comsort, Inc | 1 | $100 |
| Tempus AI, Inc | 1 | $74 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$995,573 in reported general payments places this provider in the 95th percentile of 4,567 internal medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CabometyxCabozantinib S-Malate | 85 | $1,750,512 |
| FotivdaTivozanib Hcl | 33 | $890,622 |
| InlytaAxitinib | 24 | $466,941 |
| WeliregBelzutifan | 16 | $454,714 |
| LenvimaLenvatinib Mesylate | 17 | $405,316 |
| XtandiEnzalutamide | 31 | $395,357 |
| NubeqaDarolutamide | 24 | $293,376 |
| EliquisApixaban | 19 | $18,642 |
| Abiraterone Acetate | 52 | $13,601 |
| Everolimus | 13 | $12,100 |
| Bicalutamide | 51 | $2,106 |
| Morphine Sulfate ErMorphine Sulfate | 34 | $1,209 |
| Oxycodone Hcl | 36 | $881 |
| Prednisone | 101 | $773 |
| Hydrocortisone | 26 | $735 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Exelixis Inc.Cabometyx | $212,122 | $1,750,51285 claims |
| PfizerInlyta, Eliquis | $67,810 | $485,58243 claims |
| MerckWelireg | $37,645 | $454,71416 claims |
| Eisai Inc.Lenvima | $15,151 | $405,31617 claims |
| Astellas Pharma US IncXtandi | $16,525 | $395,35731 claims |
| BayerNubeqa | $199,278 | $293,37624 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $818 | $13,60152 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,567 internal medicine providers in Michigan.
Other internal medicine in Ann Arbor
- Terry SmithAnn Arbor$2.3M
- A FendrickAnn Arbor$347K
- Gazala KhanAnn Arbor$86K
- Michael ValituttoKalamazoo$1.8M
- Tina AbrahamPontiac$834K
- Steven KatzmanLivonia$715K
- Adam FormanSouthfield$453K
- Saroj NeupaneDetroit$373K
- James BazziDearborn Heights$368K
- Mohamad HatahetWaterford$352K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.